We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know
Read MoreHide Full Article
The most recent trading session ended with Novavax (NVAX - Free Report) standing at $9.34, reflecting a +1.3% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily loss of 1.46%. Elsewhere, the Dow saw an upswing of 0.65%, while the tech-heavy Nasdaq depreciated by 3.07%.
The the stock of vaccine maker has risen by 11.35% in the past month, leading the Medical sector's gain of 1.84% and the S&P 500's gain of 1.08%.
Investors will be eagerly watching for the performance of Novavax in its upcoming earnings disclosure. The company is predicted to post an EPS of -$0.67, indicating a 53.47% growth compared to the equivalent quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $90.72 million, down 68.86% from the prior-year quarter.
It is also important to note the recent changes to analyst estimates for Novavax. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 87.5% higher within the past month. Novavax is currently a Zacks Rank #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 70, this industry ranks in the top 28% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow NVAX in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know
The most recent trading session ended with Novavax (NVAX - Free Report) standing at $9.34, reflecting a +1.3% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily loss of 1.46%. Elsewhere, the Dow saw an upswing of 0.65%, while the tech-heavy Nasdaq depreciated by 3.07%.
The the stock of vaccine maker has risen by 11.35% in the past month, leading the Medical sector's gain of 1.84% and the S&P 500's gain of 1.08%.
Investors will be eagerly watching for the performance of Novavax in its upcoming earnings disclosure. The company is predicted to post an EPS of -$0.67, indicating a 53.47% growth compared to the equivalent quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $90.72 million, down 68.86% from the prior-year quarter.
It is also important to note the recent changes to analyst estimates for Novavax. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 87.5% higher within the past month. Novavax is currently a Zacks Rank #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 70, this industry ranks in the top 28% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow NVAX in the coming trading sessions, be sure to utilize Zacks.com.